Chief Operations Officer, Cell Ready
At CellReady, Ignacio has led the company’s operational growth in the cell and gene therapy space, focusing on next-generation medicines and driving strategy and execution across partnerships with global biologics, startups, academic centers, financial institutions, and CDMOs/CROs. His leadership has shaped large-scale transformations saving millions in capital and time across advanced manufacturing, GMP operations, quality, and supply chain.
Ignacio supported pioneering the industrialization of next generation medicines including many of the first FDA-approved cell and gene therapies and led the creation of BioExcellence’s high throughput model, used to build and optimize some of the world’s largest cell therapy manufacturing facilities.
Vice President CMC, Immatics
Mamta Kalra joined Immatics in 2016 and is responsible for the manufacturing process and analytical t of autologous and allogeneic adoptive cell therapy programs. Mamta holds a PhD
in Immunology from Post Graduate Institute of Medical Education and Research in India and a postdoctoral training in adoptive T-cell therapy from the Center for Cell and Gene Therapy at Baylor College of Medicine.
Mamta has over 20 years of experience in the field of basic and applied Immunology with 13+ years in the field of cell and gene therapy. Upon joining Immatics, she led the process development for the ACTengine® program and gradually expanded her contributions to encompass diverse activities under analytical development. In addition to manufacturing advancements, Mamta promoted product and platform development for various next-generation TCR-T programs.
Manager GMP Cell Products, Seattle Children’s Therapeutics
With a career in research spanning back to 2007, Adam initially focused on natural product drug discovery. In 2011, he transitioned to Seattle Children's Hospital, where he now manages the GMP manufacturing team. He has learned pretty much everything he knows about GMP manufacturing in that time working through process and protocol development and scaling R&D to GMP. Over the years, our team has been instrumental in advancing 16 Investigational New Drugs (INDs) for various targets into clinical trials. He has had the privilege of learning and working alongside very experienced GMP minds and of course amazing research. Our driving mission is to expand access to hope, care, and life-changing cures for children.
Site Head & Scientific Director, Stanford Laboratory for Cell & Gene Medicine
Dr. Feldman is the Site Head and Scientific Director for Stanford’s Laboratory for Cell and Gene Medicine, Stanford’s GMP Cell and Gene Therapy Facility. He directs process development and manufacturing for the Stanford Center for Cancer Cell Therapy, Stanford Center for Curative and Definitive Medicine and all other users of the facility.
Dr. Feldman’s research interests include development of retroviral and lentiviral packaging cell lines and novel strategies for the large-scale closed cell culture processes to support production of clinical reagents. As a result, the lab is focused on identifying novel tumor-associated antigens and developing T cell receptors and chimeric antigen receptors to re-direct T cells to target specific tumors. Recently, research efforts have also focused on individualized cell therapies utilizin mutation-specific TIL, as well as mutation-specific TCRs to engineer T cells, targeting immunogenic mutations presented on breast cancers.
Chief Executive Officer, Multiply Labs
Fred Parietti is the co-founder and CEO of Multiply Labs, a robotics company revolutionizing cell therapy manufacturing through automation. Fred holds a PhD in Mechanical Engineering from MIT and has authored over 30 peer-reviewed robotics publications with 2,000+ citations, along with 15+ patents and patent applications. Fred leads a multidisciplinary team of engineers, scientists, and FDA experts and has raised over $25M in funding to advance Multiply Labs’ mission. Under his leadership, Multiply Labs launched the first cell therapy robotics system compatible with GMP equipment and pioneered the first industrial-scale technology for manufacturing individualized pharmaceutical capsules.
Vice President Chief Technology Officer Manufacturing Business
Division, Charles River Labs
Matt leverages his PhD in Immunology and 15+ years of experience in the field to drive the global CDMO, Testing, and Microbial Solutions strategy and portfolio expansion, working with strategic and corporate development teams to identify and pursue opportunities for growth and innovation. He works collaboratively with leadership to oversee a 24-site CGT CDMO, Testing, and Microbial Solutions network spanning the globe.
Matt has an extensive expertise in therapeutic development, across multiple modalities, as well as Process Development, Analytical Development/Qualification/Validation, Regulatory Affairs, and Quality Assurance. Having published multiple papers in high-impact journals and filed patents for novel therapeutics Matt has also prepared and submitted regulatory reports for pre-IND, IND, and IMPD filings in the US and EU.